325 related articles for article (PubMed ID: 29208671)
1.
Fang HY; Münch NS; Schottelius M; Ingermann J; Liu H; Schauer M; Stangl S; Multhoff G; Steiger K; Gerngroß C; Jesinghaus M; Weichert W; Kühl AA; Sepulveda AR; Wester HJ; Wang TC; Quante M
Clin Cancer Res; 2018 Mar; 24(5):1048-1061. PubMed ID: 29208671
[No Abstract] [Full Text] [Related]
2. High-Fat Diet Accelerates Carcinogenesis in a Mouse Model of Barrett's Esophagus via Interleukin 8 and Alterations to the Gut Microbiome.
Münch NS; Fang HY; Ingermann J; Maurer HC; Anand A; Kellner V; Sahm V; Wiethaler M; Baumeister T; Wein F; Einwächter H; Bolze F; Klingenspor M; Haller D; Kavanagh M; Lysaght J; Friedman R; Dannenberg AJ; Pollak M; Holt PR; Muthupalani S; Fox JG; Whary MT; Lee Y; Ren TY; Elliot R; Fitzgerald R; Steiger K; Schmid RM; Wang TC; Quante M
Gastroenterology; 2019 Aug; 157(2):492-506.e2. PubMed ID: 30998992
[TBL] [Abstract][Full Text] [Related]
3. Notch Signaling Mediates Differentiation in Barrett's Esophagus and Promotes Progression to Adenocarcinoma.
Kunze B; Wein F; Fang HY; Anand A; Baumeister T; Strangmann J; Gerland S; Ingermann J; Münch NS; Wiethaler M; Sahm V; Hidalgo-Sastre A; Lange S; Lightdale CJ; Bokhari A; Falk GW; Friedman RA; Ginsberg GG; Iyer PG; Jin Z; Nakagawa H; Shawber CJ; Nguyen T; Raab WJ; Dalerba P; Rustgi AK; Sepulveda AR; Wang KK; Schmid RM; Wang TC; Abrams JA; Quante M
Gastroenterology; 2020 Aug; 159(2):575-590. PubMed ID: 32325086
[TBL] [Abstract][Full Text] [Related]
4. Elimination of NF-κB signaling in Vimentin+ stromal cells attenuates tumorigenesis in a mouse model of Barrett's Esophagus.
Anand A; Fang HY; Mohammad-Shahi D; Ingermann J; Baumeister T; Strangmann J; Schmid RM; Wang TC; Quante M
Carcinogenesis; 2021 Apr; 42(3):405-413. PubMed ID: 33068426
[TBL] [Abstract][Full Text] [Related]
5. EUS followed by EMR for staging of high-grade dysplasia and early cancer in Barrett's esophagus.
Larghi A; Lightdale CJ; Memeo L; Bhagat G; Okpara N; Rotterdam H
Gastrointest Endosc; 2005 Jul; 62(1):16-23. PubMed ID: 15990814
[TBL] [Abstract][Full Text] [Related]
6. EUS in the management of the patient with dysplasia in Barrett's esophagus.
Savoy AD; Wallace MB
J Clin Gastroenterol; 2005 Apr; 39(4):263-7. PubMed ID: 15758616
[TBL] [Abstract][Full Text] [Related]
7. Immune microenvironment in Barrett's esophagus adjacent to esophageal adenocarcinoma: possible influence of adjacent mucosa on cancer development and progression.
Gokon Y; Fujishima F; Taniyama Y; Ishida H; Yamagata T; Sawai T; Uzuki M; Ichikawa H; Itakura Y; Takahashi K; Yajima N; Hagiwara M; Nishida A; Ozawa Y; Sakuma T; Kanba R; Sakamoto K; Zuguchi M; Saito M; Kamei T; Sasano H
Virchows Arch; 2020 Dec; 477(6):825-834. PubMed ID: 32533341
[TBL] [Abstract][Full Text] [Related]
8. Immune determinants of Barrett's progression to esophageal adenocarcinoma.
Lagisetty KH; McEwen DP; Nancarrow DJ; Schiebel JG; Ferrer-Torres D; Ray D; Frankel TL; Lin J; Chang AC; Kresty LA; Beer DG
JCI Insight; 2021 Jan; 6(1):. PubMed ID: 33290281
[TBL] [Abstract][Full Text] [Related]
9. CDKN2A-p16 Deletion and Activated KRAS
Sun J; Sepulveda JL; Komissarova EV; Hills C; Seckar TD; LeFevre NM; Simonyan H; Young C; Su G; Del Portillo A; Wang TC; Sepulveda AR
Cell Mol Gastroenterol Hepatol; 2024; 17(5):769-784. PubMed ID: 38296052
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.
Whitson MJ; Falk GW
Gastroenterol Clin North Am; 2015 Jun; 44(2):299-315. PubMed ID: 26021196
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells in Barrett's esophagus carcinogenesis: an inadequate microenvironment for antitumor immunity?
Somja J; Demoulin S; Roncarati P; Herfs M; Bletard N; Delvenne P; Hubert P
Am J Pathol; 2013 Jun; 182(6):2168-79. PubMed ID: 23619476
[TBL] [Abstract][Full Text] [Related]
12. Methylene blue staining of dysplastic and nondysplastic Barrett's esophagus: an in vivo and ex vivo study.
Canto MI; Setrakian S; Willis JE; Chak A; Petras RE; Sivak MV
Endoscopy; 2001 May; 33(5):391-400. PubMed ID: 11396755
[TBL] [Abstract][Full Text] [Related]
13. Volumetric laser endomicroscopy in the management of Barrett's esophagus.
Trindade AJ; Leggett CL; Chang KJ
Curr Opin Gastroenterol; 2017 Jul; 33(4):254-260. PubMed ID: 28402993
[TBL] [Abstract][Full Text] [Related]
14. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
15. Characterizing caspase-1 involvement during esophageal disease progression.
Barber G; Anand A; Katarzyna Oficjalska ; Phelan JJ; Heeran AB; Flis E; Clarke NE; Watson JA; Strangmann J; Flood B; O'Neill H; O'Toole D; MacCarthy F; Ravi N; Reynolds JV; Kay EW; Quante M; O'Sullivan J; Creagh EM
Cancer Immunol Immunother; 2020 Dec; 69(12):2635-2649. PubMed ID: 32613271
[TBL] [Abstract][Full Text] [Related]
16. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
[TBL] [Abstract][Full Text] [Related]
17. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
[TBL] [Abstract][Full Text] [Related]
18. Potential application of p53 as an intermediate biomarker in Barrett's esophagus.
Jones DR; Davidson AG; Summers CL; Murray GF; Quinlan DC
Ann Thorac Surg; 1994 Mar; 57(3):598-603. PubMed ID: 8147627
[TBL] [Abstract][Full Text] [Related]
19. A case of simultaneous esophageal squamous cell carcinoma and Barrett's adenocarcinoma.
Yamazaki T; Iwaya Y; Iwaya M; Watanabe T; Seki A; Ochi Y; Hara E; Sekiguchi T; Hosaka N; Arakura N; Tanaka E; Hasebe O
Clin J Gastroenterol; 2016 Aug; 9(4):222-7. PubMed ID: 27220657
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases.
Kazeminezhad B; Mirafsharieh SA; Dinyari K; Azizi D; Ebrahimi A
Turk J Gastroenterol; 2014 Jun; 25(3):253-6. PubMed ID: 25141312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
